Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
| Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | ||
| Ozurdex | dexamethasone | Diabetic macular edema | Do not reimburse | Complete | ||
| Ozurdex | Dexamethasone intravitreal implant | Macular edema, central retinal vein occlusion | Do not list | Complete | ||
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Active | |||
| Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Palynziq | pegvaliase | Phenylketonuria | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | ||
| Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active | ||
| pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | ||
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
| Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
| Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
| Perseris | risperidone | Schizophrenia, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Pheburane | Sodium phenylbutyrate | Urea cycle disorders | List | Complete | ||
| Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
| Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
| Pifeltro | doravirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
| Plegridy | Peginterferon beta-1a | Multiple sclerosis, relapsing-remitting | List with criteria/condition | Complete | ||
| Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024